YCR p53 Research Unit, Department of Biology, University of York, York, UK.
Cancer Biol Ther. 2011 Dec 15;12(12):1059-68. doi: 10.4161/cbt.12.12.18141.
The serine/threonine protein kinase Aurora A is known to interact with and phosphorylate tumor suppressor p53 at Serine 215 (S215), inhibiting the transcriptional activity of p53. We show that Aurora A positively regulates human p53 protein levels and, using isogenic p53 wild-type and p53-null colorectal carcinoma cells, further show that p53 regulates human Aurora A protein expression. S215 is located in the DNA-binding core of p53 and at the center of the cryptic epitope for PAb240 antibody, which is used to detect mutant and denatured p53. Following denaturing SDS PAGE, the PAb240 epitope was detectable by immunoblotting in only two out of eight cell lines. The efficacy of novel p53-targeted anticancer therapies may be influenced by the conformational state of p53, therefore, the initial determination of p53 status may be relevant. We found no correlation between phosphorylation of p53 at S215 and PAb240 antibody recognition. However, phosphorylation at S37 was positively associated with PAb240 reactivity. More importantly, we provide the first evidence of Aurora A-mediated cross-talk between N- and C-terminal p53 post-translational modifications. As p53 and Aurora A are targets for anticancer therapy the impact of their reciprocal relationship and Aurora A-induced post-translational modification of p53 should be considered.
丝氨酸/苏氨酸蛋白激酶 Aurora A 已知与肿瘤抑制因子 p53 相互作用并使其磷酸化于丝氨酸 215 位(S215),从而抑制 p53 的转录活性。我们发现 Aurora A 可正向调节人 p53 蛋白水平,并使用同基因野生型 p53 和 p53 缺失的结直肠癌细胞进一步表明 p53 调节人 Aurora A 蛋白表达。S215 位于 p53 的 DNA 结合核心区,也是 PAb240 抗体的隐匿表位的中心,该抗体用于检测突变型和失活型 p53。经过 SDS-PAGE 变性后,只有在 8 个细胞系中的 2 个细胞系中,PAb240 表位可通过免疫印迹检测到。新型 p53 靶向抗癌疗法的疗效可能受 p53 构象状态的影响,因此,p53 状态的初步确定可能是相关的。我们发现 p53 在 S215 位的磷酸化与 PAb240 抗体识别之间没有相关性。然而,S37 位的磷酸化与 PAb240 的反应性呈正相关。更重要的是,我们提供了 Aurora A 介导的 p53 翻译后修饰的 N-和 C-末端之间相互作用的首个证据。由于 p53 和 Aurora A 是抗癌治疗的靶点,因此应考虑它们相互关系的影响以及 Aurora A 诱导的 p53 翻译后修饰。